drugset / Trial / NCT02352077
NeuroRegen Scaffold™ With Stem Cells for Chronic Spinal Cord Injury Repair
Phase 1
Unknown
30 enrolled
Chinese Academy of Sciences
Affiliated Hospital of Logistics University of CAPF · collabFirst Hospitals affiliated to the China PLA General Hospital · collabThe First Affiliated Hospital of Soochow University · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety and efficacy of NeuroRegen scaffold with bone marrow mononuclear cells (BMMCs) or mesenchymal stem cells (MSCs) in patients with chronic spinal cord injury.
Timeline
- Start
- 2015-01
- Primary completion
- 2021-12
- Completion
- 2021-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | bone marrow mononuclear cells | Cell therapy | — | — |
| Subject | mesenchymal stem cells | Cell therapy | — | — |